Opus Genetics (IRD) Stock Price

Opus Genetics Price

NASDAQ·CLOSED
4.63
​
Market closed

Revenue has compounded at 31.3% per year over the past 19 years to 14.20 M USD. Opus Genetics's net margin stands at -349.3%, up from -9,625.3% several years earlier. Analysts set a median price target of 9.00 USD, implying 94.6% above the current price. Of 23 analysts, 22 rate the stock a buy — an overall Buy consensus.

Opus Genetics stock price

Access this data via the Eulerpool API

Opus Genetics business model & stock analysis

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 9 full-time employees. The company went IPO on 2004-11-30. The firm is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its pipeline includes two small molecule product candidates targeting several of such indications. Nyxol Eye Drops (Nyxol) is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically induced mydriasis (RM), presbyopia (age-related blurry near vision) and dim light or night vision disturbances (DLD) (halos, glares and starbursts). Its product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases. The firm has also in-licensed APX2009 and APX2014, which are second-generation product candidates and analogs of APX3330.

Frequently asked questions about Opus Genetics

Analysts currently set an average price target of 9.00 USD for the Opus Genetics stock (median: 9.00 USD), implying +94.6 % versus the latest price. The consensus is based on 23 analyst ratings.

23 analysts currently rate the Opus Genetics stock: 22 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Opus Genetics to generate revenue of 11.54 M USD and earnings per share of -0.12 USD.

Converted at the current exchange rate, the Opus Genetics share trades at 4.13 EUR (4.63 USD).

The Opus Genetics share (IRD) is listed on 4 stock exchanges, including: NASDAQ (OCUP), Frankfurt (R3X1.F), München (R3X1.MU), Düsseldorf (R3X1.DU).

The expected revenue of Opus Genetics is 11.54 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Opus Genetics is -71.56 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Opus Genetics is currently -40.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Opus Genetics stock.

The price-to-sales ratio (P/S) of Opus Genetics is currently 249.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Opus Genetics stock.

The Eulerpool Quality Score for Opus Genetics is 2/10.

The ISIN of Opus Genetics is US67577R1023. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Opus Genetics is A2QG4Z. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Opus Genetics is IRD. The ticker symbol is used to trade Opus Genetics shares on the stock exchange.

Fair ValueTerminal
4.58 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
525,777.78 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website ocuphire.com
Currency
USD
Initial public offering
Nov 30, 2004
ISIN
US67577R1023
Cusip
67577R102
Market capitalization
318.94 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-40.22
P/Ee 2027
-59.42
P/Ee 2028
-151.20
P/Ee 2029
-578.66
P/Ee 2030
11.34
P/Se
249.45
EV/EBIT
—
P/B Ratio
20.78
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-300.97 %
Last updated Oct 9, 2026, 9:54 PM

Opus Genetics Peer Group

Opus Genetics Ticker

DÜSSELDORF · R3X1.DUFRANKFURT · R3X1.FMUNICH · R3X1.MUNASDAQ · OCUP

Opus Genetics FIGI

OCUP:US · BBG000BT34Q3OCUP:UA · BBG000BT35N3OCUP:UC · BBG000BT3606OCUP:UN · BBG000BT3811OCUP:UP · BBG000BT3884OCUP:UB · BBG000BT3928OCUP:UM · BBG000BT3BS5OCUP:UX · BBG000BT3C58OCUP:UR · BBG000BT3CH5OCUP:UD · BBG000BT3FH8OCUP:UF · BBG000BT3J26OCUP:VY · BBG000BT3J80